AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

Merck & Co., Inc. is still a pharmaceutical standout, even after Goldman Sachs adjusted its market outlook. The firm revised ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

An encouraging quarterly earnings report was dampened by a new demand from President Trump.

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, ...

AbbVie's pair of immunology drugs is expected to help drive growth into the next decade. The company should successfully improve its lineup thanks to its deep pipeline. AbbVie can overcome tariff ...

AbbVie is paying Ichnos Glenmark Innovation (IGI) $700 million upfront for a next-generation rival to Johnson & Johnson’s Tecvayli, positioning the Big Pharma to advance a new option for ...

WORCESTER ― Pharmaceutical company AbbVie Inc. is looking to build a three-story addition to its building near where Belmont and Plantation streets meet. With a total area of about 55,200 square ...